報價延遲最少15分鐘:2026/02/04 07:18 EST
盤前時段
|
||||
|
5.49 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.47
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.07/-1.44
|
|
企業價值
696.44M
|
| 資產負債 |
|
每股賬面淨值
1.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
20.00K
|
|
每股收益
0.00
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide. |
